Formulary
Tick-borne encephalitis vaccine: Indications, Dosing, Side Effects and Interactions
For tick-borne encephalitis vaccine Tick-borne encephalitis vaccine is an inactivated vaccine containing adsorbed tick-borne encephalitis virus.
MedNext Academy | 5 min read
Tick-borne encephalitis vaccine: Indications, Dosing, Side Effects and Interactions
For tick-borne encephalitis vaccine Tick-borne encephalitis vaccine is an inactivated vaccine containing adsorbed tick-borne encephalitis virus.
Drug action
For tick-borne encephalitis vaccine Tick-borne encephalitis vaccine is an inactivated vaccine containing adsorbed tick-borne encephalitis virus.
Indications and dose
**Initial immunisation against tick-borne encephalitis**
- **Child** (By Intramuscular Injection): 16-17 years 0.5 mL for 1 dose, followed by 0.5 mL after 1-3 months for 1 dose, then 0.5 mL after further 5-12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.
- **Adult** (By Intramuscular Injection): 0.5 mL for 1 dose, followed by 0.5 mL after 1-3 months for 1 dose, then 0.5 mL after further 5-12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.
- **Elderly** (By Intramuscular Injection): 0.5 mL for 1 dose, followed by 0.5 mL after 1-3 months for 1 dose, then 0.5 mL after further 5-12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.
**Immunisation against tick-borne encephalitis, booster doses**
- **Child** (By Intramuscular Injection): 1-17 years First dose to be given within 3 years after initial course completed and then every 3-5 years, dose to be administered in deltoid region or anterolateral thigh in infants (consult product literature).
- **Adult** (By Intramuscular Injection): First dose to be given within 3 years after initial course completed and then every 3-5 years, dose to be administered in deltoid region (consult product literature).
**Initial immunisation against tick-borne encephalitis for tick-borne encephalitis vaccine**
- **Child 1-15 years** (By intramuscular injection): 0.25 mL for 1 dose, followed by 0.25 mL after 1-3 months for 1 dose, then 0.25 mL after further 5-12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.
- **Child 16-17 years** (By intramuscular injection): 0.5 mL for 1 dose, followed by 0.5 mL after 1-3 months for 1 dose, then 0.5 mL after further 5-12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved.
**Immunisation against tick-borne encephalitis, booster doses for tick-borne encephalitis vaccine**
- **Child 1-17 years** (By intramuscular injection): First dose to be given within 3 years after initial course completed and then every 3-5 years, dose to be administered in deltoid region or anterolateral thigh in infants (consult product literature).
Cautions
For all vaccines, general Acute illness; minor illnesses Cautions, further information Illness UKHSA advises vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset. Predisposition to neurological problems UKHSA advises: when there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is recommended ; advice on the management of fever should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is recommended ; children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule; when there is a still evolving neurological problem , including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is recommended if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable. Impaired immune response and drugs affecting immune response Immune response to vaccines may be reduced in immunosuppressed patients, UKHSA advises consider seeking specialist advice.
Side effects
For all vaccines, general Common or very common Abdominal pain; appetite decreased; arthralgia; diarrhoea; dizziness; fatigue; fever; headache; lymphadenopathy; malaise; myalgia; nausea; skin reactions; vomiting Uncommon Hypersensitivity Side-effects For tick-borne encephalitis vaccine Common or very common Restlessness (in children); sleep disorder (in children) Rare or very rare Asthenia; autoimmune disorder (in adults); chills (uncommon in children); demyelination (in adults); drowsiness (in adults); dyspepsia (in children); dyspnoea; eye pain; gait abnormal; hyperhidrosis; increased risk of infection; influenza like illness; joint swelling (in adults); meningism; meningitis aseptic (in adults); motor dysfunction; musculoskeletal stiffness; nerve disorders; oedema; pain; seizures; sensory disorder; tachycardia (in adults); tinnitus; vertigo; vision disorders
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Tick-borne encephalitis vaccine in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary